Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2/3 1

Status

Unknown 4

Sponsor Class

OTHER 4INDUSTRY 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 67Lung Neoplasms 29Brain Neoplasms 11Head and Neck Neoplasms 10Neoplasms 9Esophageal Neoplasms 9Breast Neoplasms 8Adenocarcinoma of Lung 8Adenocarcinoma Of Esophagus 7Glioblastoma 6Gliosarcoma 5Esophageal Squamous Cell Carcinoma 5NSCLC 4Central Nervous System Neoplasms 4Adenocarcinoma, Bronchiolo-Alveolar 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Colonic Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 2Stomach Neoplasms 2Osteosarcoma 2Oligodendroglioma 2Neuroblastoma 2Lymphoid Interstitial Pneumonia 2Laryngeal Diseases 2Glioma 2

Interventions

Pemetrexed 9Drug Therapy 9osimertinib 7Radiotherapy 6Carboplatin 6anlotinib 5Radiosurgery 5aflutinib 4Gefitinib 4Docetaxel 4Cisplatin 4tislelizumab 3pembrolizumab 3icotinib 3Vinorelbine 3Paclitaxel 3Gemcitabine 3Erlotinib Hydrochloride 3toripalimab 2dacomitinib 2camrelizumab 2apatinib 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2Liquid Biopsy 2Immune Checkpoint Inhibitors 2Chemotherapy, Adjuvant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × NSCLC × Gefitinib × Clear all
NCT04575415 2020-10-20

BELLA

Guangdong Association of Clinical Trials

Unknown
272 enrolled
Thoracic

NSCLC

NCT04007835 2019-07-05

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Guangdong Association of Clinical Trials

Phase NA Unknown
120 enrolled
Thoracic

NSCLC

NCT03656393 2018-09-04

RCTACSCNSCLC

Shenzhen People's Hospital

Phase 3 Unknown
48 enrolled
Thoracic

NSCLC

NCT02387086 2015-03-12

Gefitinib Combined With Thalidomide to Treat NSCLC

Shaanxi Provincial People's Hospital

Phase 2/3 Unknown
380 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡